MedTrace Logo

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2018-09-25

No results posted yet for this study

Summary

The purpose of this study is to determine if VF001-DP improves wound healing in chronic venous leg ulcers compared to standard care only.

Conditions

  • Ulcer
  • Leg Ulcer
  • Varicose Ulcer
  • Pathologic Processes
  • Skin Ulcer
  • Skin Diseases
  • Vascular Diseases
  • Cardiovascular Diseases

Interventions

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

VF001-DP LD

VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.

BIOLOGICAL

VF001-DP HD

VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • ARANZ Medical

    collaborator OTHER

  • ALMAC Clinical Services

    collaborator INDUSTRY

  • Factor Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • William Marston, MD · UNC-Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-11-30
Completion
2019-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973893 on ClinicalTrials.gov